ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97

New research, clinical trial outcomes, etc.
Post Reply
D.ap
Senior Member
Posts: 4108
Joined: Fri Jan 18, 2013 11:19 am

ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97

Post by D.ap »

ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97


07 February 2024
Abstract

The t(X,17) chromosomal translocation, generating the ASPSCR1::TFE3 fusion oncoprotein, is the singular genetic driver of alveolar soft part sarcoma (ASPS) and some Xp11-rearranged renal cell carcinomas (RCCs), frustrating efforts to identify therapeutic targets for these rare cancers. Here, proteomic analysis identifies VCP/p97, an AAA+ ATPase with known segregase function, as strongly enriched in co-immunoprecipitated nuclear complexes with ASPSCR1::TFE3. We demonstrate that VCP is a likely obligate co-factor of ASPSCR1::TFE3, one of the only such fusion oncoprotein co-factors identified in cancer biology. Specifically, VCP co-distributes with ASPSCR1::TFE3 across chromatin in association with enhancers genome-wide. VCP presence, its hexameric assembly, and its enzymatic function orchestrate the oncogenic transcriptional signature of ASPSCR1::TFE3, by facilitating assembly of higher-order chromatin conformation structures demonstrated by HiChIP. Finally, ASPSCR1::TFE3 and VCP demonstrate co-dependence for cancer cell proliferation and tumorigenesis in vitro and in ASPS and RCC mouse models, underscoring VCP’s potential as a novel therapeutic target.


https://www.nature.com/articles/s41467-024-45280-5
Debbie
Post Reply

Return to “Medical Publications”